Gene therapy safety check: researchers track hepatitis b patients years after treatment
NCT ID NCT07254208
First seen Dec 08, 2025 · Last updated Apr 28, 2026 · Updated 14 times
Summary
This study follows 45 people with chronic hepatitis B who have already received the experimental gene therapy PBGENE-HBV in an earlier trial. Researchers will monitor them for delayed side effects over time. No new treatment is given; the goal is to understand the long-term safety of the gene editing product.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC HBV INFECTION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
ICS ARENSIA Exploratory Medicine SRL
Chisinau, Moldova, 2025, Moldova
-
Massachusetts General Hospital/Harvard University
Boston, Massachusetts, 02114, United States
-
New Zealand Clinical Research
Auckland, New Zealand, 1010, New Zealand
-
Queen Mary Hospital, University of Hong Kong
Hong Kong, Hong Kong, Hong Kong
Conditions
Explore the condition pages connected to this study.